Erectile Dysfunction Treatment: Comparative Efficacy and Safety of Nutrition, Dietary Supplements, Lifestyle Intervention, and Medical Therapy — A Narrative Review
Updated: Sep 24
Registered Dietitian (Israel)
Founder, Healthy Habits Coaching
Abstract
Background
Erectile dysfunction (ED) is a multifactorial disorder with vascular, metabolic, endocrine, neurological, medication-related, and psychological determinants. In addition to its effects on sexual health and quality of life, ED has important cardiovascular implications. Interest in dietary strategies and nutritional supplements for ED has increased, but their efficacy must be interpreted relative to established medical therapies.
Objective
This narrative review evaluates contemporary evidence regarding the efficacy and safety of lifestyle modification, nutrition, dietary supplements, and established medical therapies for ED. Particular attention is given to the comparative effectiveness of phosphodiesterase type 5 inhibitors (PDE5Is)—sildenafil, tadalafil, vardenafil, and avanafil—and to whether commonly promoted nutritional supplements provide clinically meaningful benefits.
Methods
A targeted narrative synthesis was based primarily on recent umbrella reviews, systematic reviews and meta-analyses, together with contemporary clinical guidance and consensus recommendations. Priority was given to PubMed-indexed evidence, including a 2026 umbrella review of ED treatments, a 2026 dose-specific network meta-analysis of PDE5 inhibitors, systematic reviews of dietary supplements and dietary patterns, randomized-trial evidence concerning lifestyle intervention, European Association of Urology (EAU) guidance, and the Princeton IV Consensus. Because this article is a narrative review rather than a prospectively registered systematic review, it does not claim exhaustive retrieval of all available studies.
Results
PDE5 inhibitors have substantially stronger evidence for treatment of established ED than nutritional supplements. A 2026 network meta-analysis of 83 double-blind, placebo-controlled randomized trials involving 6,029 participants found sildenafil to have the strongest efficacy signal among evaluated on-demand PDE5I regimens. Sildenafil 100 mg produced an odds ratio (OR) of 9.06 for satisfactory erectile function relative to placebo, followed by sildenafil 50 mg (OR 7.90), vardenafil 10 mg (OR 7.78), tadalafil 20 mg (OR 7.13), avanafil 200 mg (OR 3.42), tadalafil 10 mg (OR 3.14), and avanafil 100 mg (OR 1.75). Treatment-related adverse events were ranked highest with vardenafil and lowest with tadalafil, although uncertainty was substantial for some estimates.
Lifestyle intervention provides a smaller but clinically relevant adjunctive benefit. A 2026 meta-analysis of 16 randomized controlled trials involving 1,477 participants found a mean improvement in erectile-function scores of 2.35 points (95% CI 1.68–3.01), with moderate certainty of evidence. Dietary evidence suggests associations between healthier dietary patterns and better erectile outcomes, but heterogeneous study designs limit causal interpretation.
Among nutritional supplements, L-arginine has evidence for a small improvement in erectile function, whereas ginseng appears to provide only trivial benefit according to contemporary guideline assessment. Evidence supporting folic acid and other antioxidants remains insufficient to establish them as standard ED treatments. Commercial multi-ingredient supplements are particularly problematic because marketed formulations may contain inadequately studied ingredients or doses.
Conclusions
For men who are appropriate candidates for pharmacological treatment, PDE5 inhibitors remain the most strongly supported oral treatment for ED. Current comparative randomized evidence favors sildenafil for maximal on-demand efficacy, whereas tadalafil appears to have a particularly favorable overall tolerability profile and offers the additional advantage of prolonged duration of action. Lifestyle intervention should be incorporated because of its broader vascular and metabolic benefits, but its average ED-specific effect is smaller than that of PDE5 inhibitors. L-arginine may provide modest benefit in selected patients; evidence for ginseng, folic acid, and most commercial ED supplements is considerably weaker. Treatment should be individualized according to ED etiology, cardiovascular status, medications, adverse-effect susceptibility, patient preference, and treatment goals.
Keywords: erectile dysfunction; sildenafil; tadalafil; vardenafil; avanafil; PDE5 inhibitors; nutrition; L-arginine; ginseng; dietary supplements; lifestyle; cardiovascular disease
1. Introduction
Erectile dysfunction is generally characterized by persistent difficulty attaining or maintaining an erection sufficient for satisfactory sexual activity. Although ED is frequently discussed primarily as a sexual disorder, contemporary evidence supports a considerably broader clinical interpretation.
Normal erectile function depends on intact neural signaling, endothelial function, nitric-oxide-mediated vascular responses, adequate penile arterial inflow, appropriate smooth-muscle relaxation, and competent veno-occlusion. Consequently, vascular and metabolic diseases can adversely affect erectile function.
The relationship between ED and cardiovascular disease is particularly important. The Princeton IV Consensus recommends that clinicians recognize men presenting with ED as potentially being at increased cardiovascular risk and emphasizes cardiovascular risk assessment as an important component of ED evaluation. [1]
This relationship also explains why nutrition and lifestyle interventions have a plausible role in management. Hypertension, dyslipidemia, diabetes, excess adiposity, smoking, and physical inactivity can affect both cardiovascular and erectile health.
Nevertheless, biological plausibility should not be confused with therapeutic equivalence. Prescription ED medications, dietary interventions, and nutritional supplements have markedly different levels of supporting evidence.
A recent umbrella review illustrates this uncertainty. Ma and colleagues evaluated 23 meta-analyses containing 42 summary effects across 36 interventions. Using AMSTAR-2, 13 of the 23 meta-analyses (56.5%) were rated critically low quality, seven (30.5%) low quality, two (8.7%) moderate quality, and only one (4.3%) high quality. Among 42 summary effects, 95.2% were classified as either low- or very-low-quality evidence. [2]
Accordingly, the purpose of this narrative review is not simply to identify interventions associated with statistically significant changes. Rather, it is to distinguish treatments with strong evidence and clinically meaningful efficacy from interventions supported primarily by limited, heterogeneous, or low-certainty evidence.
2. ED as a Cardiometabolic and Sexual-Health Condition
Persistent ED warrants clinical evaluation rather than immediate self-treatment with a dietary supplement.
The Princeton IV Consensus emphasizes the relationship between ED and cardiovascular disease and recommends cardiovascular risk assessment in appropriate men presenting with ED. [1]
Clinical assessment should consider the possibility of vascular disease, diabetes, dyslipidemia, hypertension, endocrine disorders, neurological disease, medication effects, psychological factors, and other causes.
This distinction is important because treating the symptom without identifying the underlying condition can delay recognition of clinically important disease.
From a nutritional perspective, the relationship between ED and cardiometabolic health also provides the strongest rationale for dietary intervention. Nutrition should therefore be understood primarily as one component of comprehensive vascular and metabolic risk management rather than as an alternative to medical evaluation.
3. Lifestyle Intervention
Lifestyle modification is one of the better-supported nonpharmacological components of ED management.
A 2026 systematic review and meta-analysis specifically examined randomized controlled trials of diet- and/or exercise-based lifestyle interventions. Sixteen trials involving 1,477 participants were included.
Compared with control conditions, lifestyle intervention significantly improved erectile function:
Mean difference: 2.35 points95% CI: 1.68–3.01I² = 53%.
Importantly, statistically significant improvements were observed with diet-only, exercise-only, and combined diet-and-exercise interventions. No intervention type demonstrated clear superiority over the others.
The certainty of evidence was rated moderate. [3]
This is important because it provides randomized evidence rather than relying exclusively on epidemiological associations.
Nevertheless, the magnitude of benefit should be interpreted appropriately. Lifestyle treatment produced a modest average improvement and should not be presented as equivalent to pharmacological therapy for men with established ED requiring greater symptomatic improvement.
Its value extends beyond erectile function, however. Improvements in physical activity, diet quality, blood pressure, glycemic control, cardiovascular fitness, and other metabolic factors may address conditions contributing to both ED and long-term cardiovascular risk.
Lifestyle intervention is therefore best characterized as an important adjunctive and health-promoting component of treatment, rather than as a guaranteed substitute for ED medication.
4. Dietary Patterns and Erectile Function
Dietary-pattern research provides additional support for nutritional intervention, although interpretation requires greater caution because the evidence includes observational as well as interventional research.
A systematic review and meta-analysis including 14 studies and 27,389 participants reported associations between several dietary patterns and erectile outcomes.
Plant-based dietary patterns were associated with lower odds of ED:
OR 0.71; 95% CI 0.66–0.75.
Diets rich in fruits and vegetables were also associated with lower ED risk:
OR 0.97; 95% CI 0.96–0.98.
Nut consumption was associated with lower odds:
OR 0.54; 95% CI 0.37–0.80.
Combined diet-and-exercise interventions were associated with reduced likelihood of ED:
OR 0.49; 95% CI 0.28–0.85. [4]
The investigators concluded that Mediterranean-type and other dietary patterns rich in plant foods, fruits, vegetables, and nuts may benefit ED management.
These findings should not be interpreted as proof that a specific food treats ED. Some included evidence was observational, meaning that healthier diet may coexist with other favorable behaviors and health characteristics.
The more scientifically defensible conclusion is that cardioprotective dietary patterns appear compatible with better erectile health and may contribute to ED management, particularly through improvements in vascular and metabolic health.
5. Medical Therapy: PDE5 Inhibitors
PDE5 inhibitors represent the principal established oral pharmacological treatment for ED.
The four major agents are:
sildenafil, tadalafil, vardenafil, and avanafil.
All four improve erectile function compared with placebo. However, contemporary evidence now permits a more direct comparison of their relative efficacy at specific on-demand doses.
A 2026 systematic review and network meta-analysis included 83 randomized, double-blind, placebo-controlled trials involving 6,029 participants. The analysis evaluated satisfactory erectile function, defined as an International Index of Erectile Function erectile-function domain score greater than 26. [5]
The dose-specific efficacy results relative to placebo were:
Sildenafil 100 mg: OR 9.06
Sildenafil 50 mg: OR 7.90
Vardenafil 10 mg: OR 7.78
Tadalafil 20 mg: OR 7.13
Avanafil 200 mg: OR 3.42
Tadalafil 10 mg: OR 3.14
Avanafil 100 mg: OR 1.75 [5]
These results provide a clearer efficacy hierarchy than was previously available.
6. Sildenafil: Highest-Ranked On-Demand Efficacy
Among the four PDE5 inhibitors evaluated in the recent dose-specific network meta-analysis, sildenafil demonstrated the greatest efficacy.
Sildenafil 100 mg produced an OR of 9.06 for satisfactory erectile function relative to placebo, while sildenafil 50 mg produced an OR of 7.90. [5]
The investigators concluded that sildenafil showed significantly greater efficacy than the other evaluated PDE5 inhibitors.
This finding is important because it permits a more specific statement than simply saying that all PDE5 inhibitors are effective.
Based on currently available dose-specific comparative randomized evidence:
Sildenafil has the strongest evidence for maximizing on-demand erectile efficacy among the four major PDE5 inhibitors.
This conclusion should nevertheless be restricted to the context studied: on-demand PDE5I therapy. It does not establish sildenafil as the best medication for every patient.
Individual treatment selection depends on tolerability, duration of action, frequency and timing of sexual activity, comorbidities, interacting medications, previous treatment response, and patient preference.
7. Tadalafil: High Efficacy With a Favorable Tolerability Profile
Tadalafil is also highly effective.
In the 2026 network meta-analysis, tadalafil 20 mg produced an OR of 7.13 for satisfactory erectile function compared with placebo. [5]
Although this efficacy estimate was below that of sildenafil 100 mg and sildenafil 50 mg, tadalafil has other clinically important characteristics.
Its prolonged duration of action permits a substantially wider window for sexual activity than shorter-acting PDE5 inhibitors. Tadalafil can also be administered as a daily regimen in appropriate patients.
Most importantly for comparative safety, the 2026 network meta-analysis found that the odds of treatment-related adverse events were lowest with tadalafil among the four PDE5 inhibitors evaluated. [5]
This finding supports describing tadalafil as having a particularly favorable efficacy–tolerability balance.
It would, however, be scientifically inappropriate to describe tadalafil as universally the “safest” ED medication. Safety is patient-specific, and some of the adverse-event estimates in the network meta-analysis had wide confidence intervals.
The appropriate interpretation is:
Tadalafil provides high efficacy and was associated with the lowest overall treatment-related adverse-event ranking among the four PDE5 inhibitors in the recent network meta-analysis.
8. Vardenafil
Vardenafil remains a highly effective PDE5 inhibitor.
Vardenafil 10 mg produced an OR of 7.78 for satisfactory erectile function compared with placebo in the 2026 network meta-analysis. [5]
This placed its efficacy estimate close to sildenafil 50 mg and tadalafil 20 mg.
However, the same analysis found that the odds of treatment-related adverse events were highest with vardenafil, followed by avanafil and sildenafil, with tadalafil lowest.
The authors emphasized uncertainty around some safety estimates because of wide confidence intervals. [5]
Consequently, the available evidence supports describing vardenafil as highly effective, but does not demonstrate a consistent overall advantage over sildenafil or tadalafil.
9. Avanafil
Avanafil is an effective PDE5 inhibitor but ranked below sildenafil and several commonly used doses of tadalafil and vardenafil for efficacy in the recent network meta-analysis.
Avanafil 200 mg produced:
OR 3.42
and avanafil 100 mg:
OR 1.75
for satisfactory erectile function compared with placebo. [5]
These findings should not be interpreted as evidence that avanafil is ineffective. Rather, they indicate that its relative efficacy was lower in this particular dose-specific network comparison.
Treatment choice remains individualized because pharmacokinetic characteristics and tolerability may matter substantially to individual patients.
10. Safety of PDE5 Inhibitors
Comparative safety requires more careful interpretation than comparative efficacy.
The 2026 network meta-analysis ranked the odds of treatment-related adverse events from highest to lowest as:
vardenafil → avanafil → sildenafil → tadalafil. [5]
However, wide confidence intervals around some estimates mean this should not be interpreted as an absolute safety hierarchy applicable to every patient.
PDE5 inhibitors are generally well tolerated in appropriately selected patients, but individual agents have somewhat different adverse-effect profiles.
More importantly, safety depends heavily on concurrent medications and cardiovascular status.
The most clinically important class-wide contraindication concerns nitrates. PDE5 inhibitors should not be combined with nitrate therapy because the interaction can produce clinically dangerous hypotension.
Therefore, medication reconciliation and cardiovascular assessment are essential before treatment.
The Princeton IV Consensus specifically addresses optimization of PDE5I treatment in men with ED and cardiovascular disease and emphasizes the cardiovascular implications of an ED presentation. [1]
11. PDE5 Inhibitors Versus Nutritional Supplements
One of the most important conclusions of this review is that prescription PDE5 inhibitors and nutritional supplements should not be presented as therapeutically equivalent.
The evidence supporting sildenafil, tadalafil, vardenafil, and avanafil includes large numbers of randomized controlled trials and direct comparative meta-analytic evidence.
The supplement evidence is considerably weaker.
Contemporary EAU guidance provides a strong recommendation for PDE5 inhibitors as first-line treatment. In contrast, L-arginine and ginseng receive only a weak recommendation for men with mild ED who decline pharmacological treatment, with counseling that improvement may be mild. [6]
This difference in recommendation strength reflects an important difference in evidence.
12. L-Arginine
Among nutritional supplements, L-arginine has one of the more plausible mechanisms and comparatively stronger evidence.
L-arginine is a substrate involved in nitric oxide synthesis, providing a biologically plausible mechanism through which supplementation could influence penile vascular function.
Current EAU guidance summarizes meta-analytic evidence showing that L-arginine produces a small but statistically significant improvement in erectile function.
The reported mean increase in IIEF erectile-function score was:
2.74 points95% CI: 1.67–3.81
compared with placebo. [6]
However, the guideline specifically cautions that this magnitude of improvement may not be perceived as significant by patients.
This distinction is essential.
Statistical significance does not necessarily equal clinically meaningful improvement.
L-arginine should therefore be characterized as:
Potentially effective, but with a modest average effect.
It is not supported as an efficacy-equivalent alternative to sildenafil or tadalafil.
For men with mild ED who decline conventional pharmacological therapy, it may represent an option after appropriate clinical assessment and discussion of the limited expected benefit.
13. Ginseng
Ginseng is one of the most widely promoted botanical treatments for ED, but contemporary evidence does not justify strong efficacy claims.
The EAU guideline cites Cochrane evidence concluding that ginseng may have only trivial effects on erectile function or satisfaction with intercourse compared with placebo when evaluated using validated instruments. [6]
This is an important finding because ginseng is frequently marketed as though it were a natural substitute for PDE5 inhibitors.
The evidence does not support such equivalence.
Ginseng can therefore be characterized as:
Expected efficacy: low or trivial.
Certainty: limited.
Clinical role: substantially weaker than established PDE5-inhibitor therapy.
14. Folate and Other Antioxidants
Folate, L-citrulline, L-carnitine, vitamin E, pine-bark extract, trans-resveratrol, nicotinic acid, myoinositol, and other antioxidant or nutraceutical interventions have also been investigated.
Current EAU guidance notes small positive effects from antioxidant strategies but emphasizes that these improvements may not be clinically perceptible to patients. [6]
Evidence for folic acid is therefore insufficient to support its routine use as a stand-alone ED treatment in men without an established indication for folate supplementation.
This distinction is particularly important for nutrition professionals.
Correcting a documented nutritional deficiency is evidence-based nutritional care. Prescribing the same nutrient pharmacologically to all men with ED requires separate evidence of efficacy.
Those two clinical situations should not be conflated.
15. Commercial Multi-Ingredient ED Supplements
The evidence becomes still weaker when individual nutraceutical studies are extrapolated to commercial “male enhancement” products.
A 2023 systematic review and analysis of commercially marketed ED supplements evaluated individual active ingredients and the doses contained within actual products.
Only:
2 products (8%) were categorized as having higher expected efficacy;
3 products (12%) were categorized in the lower-efficacy group;
while:
20 products (80%) met criteria for no expected efficacy under the investigators' scoring approach. [7]
The authors found that marketed supplements frequently combined numerous ingredients at negligible doses or included ingredients without adequate supporting evidence.
This illustrates an important methodological problem.
Evidence that a specific amount of L-arginine, for example, produced an effect in a randomized trial cannot automatically be transferred to a commercial product containing a much smaller amount of L-arginine mixed with numerous other compounds.
Accordingly, commercial ED supplements should not be assumed effective merely because their ingredient lists contain substances that have individually been investigated.
16. Comparative Efficacy Hierarchy
Based on the evidence reviewed, several conclusions can be stated with reasonable confidence.
Among oral pharmacological treatments, sildenafil currently has the strongest dose-specific comparative evidence for maximal on-demand efficacy.
Tadalafil also demonstrates high efficacy and appears to provide a particularly favorable balance between efficacy and overall tolerability.
Vardenafil is highly effective but does not demonstrate a clear overall advantage over sildenafil or tadalafil.
Avanafil is effective but ranked lower for efficacy in the recent dose-specific network meta-analysis.
Lifestyle intervention produces a statistically significant but more modest improvement and should be viewed as an adjunctive strategy with important broader cardiometabolic benefits.
Among supplements, L-arginine has evidence for a small improvement but is clearly less established than PDE5 inhibitors.
Ginseng appears to have only trivial average effects according to current guideline interpretation.
Evidence for folic acid and other antioxidants is insufficient to support their routine use as established ED therapy.
Commercial multi-ingredient supplements have particularly uncertain efficacy because product formulation frequently does not correspond to the doses and ingredients investigated in clinical trials.
17. Comparative Safety
Safety should not be equated simply with the number of adverse effects reported in clinical trials.
Lifestyle interventions generally offer the broadest health benefits when appropriately prescribed, but they may not provide sufficient symptomatic improvement for established moderate or severe ED.
PDE5 inhibitors have extensive clinical evidence and are generally well tolerated in appropriately selected patients.
Among the four major PDE5 inhibitors, tadalafil had the lowest treatment-related adverse-event ranking in the 2026 network meta-analysis, while vardenafil had the highest. [5]
However, this ranking does not mean tadalafil is appropriate or safest for every individual.
The presence of nitrate therapy represents a major safety issue for the PDE5I class, and cardiovascular status and concurrent medication use must be assessed.
Nutritional supplements may appear safer because they are available without prescription, but this assumption is not scientifically justified. Supplement evidence is less extensive, commercial formulations may differ from studied preparations, and efficacy and safety cannot necessarily be extrapolated from a single ingredient to a multi-ingredient commercial formulation.
Therefore, the strongest safety conclusion is not that “natural treatments are safer,” but that safety must be assessed according to the specific intervention, dose, product, patient, comorbidities, and concurrent medications.
18. Practical Evidence-Based Treatment Perspective
For a patient presenting with persistent ED, treatment should begin with identification of potential causes and cardiovascular/metabolic risk rather than immediate selection of a supplement.
Lifestyle and dietary management should be incorporated where appropriate because randomized evidence demonstrates modest improvement in erectile function and because these interventions address broader vascular and metabolic health.
When oral pharmacological therapy is appropriate, PDE5 inhibitors have the strongest evidence.
If maximal on-demand efficacy is the primary consideration, current comparative evidence favors sildenafil.
If high efficacy combined with long duration and favorable overall tolerability is prioritized, tadalafil is particularly attractive.
Vardenafil remains highly effective, while avanafil represents another effective PDE5I option.
For individuals who decline pharmacological treatment and have mild ED, L-arginine may be discussed with realistic expectations that the average benefit is small.
Ginseng should not be represented as equivalent to prescription therapy because the best available evidence suggests only trivial improvement.
Folic acid and other antioxidant supplements should not be routinely prescribed solely for ED without stronger evidence or another established nutritional indication.
19. Limitations of the Evidence
Several limitations must be acknowledged.
First, even the broader ED treatment literature contains substantial methodological weakness.
The 2026 umbrella review found that 56.5% of included meta-analyses were critically low quality and another 30.5% were low quality according to AMSTAR-2. [2]
Therefore, the presence of a meta-analysis should not itself be interpreted as evidence of high certainty.
Second, ED is heterogeneous. Vascular ED, diabetes-associated ED, post-prostatectomy ED, medication-related ED, psychogenic ED, and mixed ED may respond differently to treatment.
Third, treatment outcomes differ among studies. Changes in IIEF, IIEF-5, erectile-function domains, erectile hardness, successful intercourse, and patient satisfaction cannot always be compared directly.
Fourth, the supplement literature is characterized by variation in ingredient preparation, dosage, duration, and study quality.
Fifth, statistically significant improvements may not reach thresholds that patients perceive as clinically meaningful.
Finally, this article is a narrative review, not a prospectively registered systematic review. It synthesizes recent high-level evidence but should not be interpreted as an exhaustive quantitative review of every ED treatment trial.
20. Discussion
The central finding of the contemporary literature is the substantial difference between the evidence supporting established pharmacological therapy and the evidence supporting dietary supplements.
PDE5 inhibitors have a large randomized evidence base, and contemporary network meta-analysis permits meaningful dose-specific comparison. Among the evaluated on-demand regimens, sildenafil demonstrated the greatest efficacy, particularly at 100 mg and 50 mg doses. [5]
Tadalafil occupies a somewhat different clinical position. Although its maximal efficacy did not exceed sildenafil in the recent network analysis, it remained highly effective and had the lowest treatment-related adverse-event ranking. Its prolonged duration of action further differentiates it clinically.
These findings demonstrate why treatment selection cannot be reduced to a single ranking.
The most efficacious treatment is not necessarily the treatment with the most favorable tolerability or convenience profile.
Nutrition and lifestyle intervention occupy another distinct position. Their average ED-specific effects are smaller than those observed with effective pharmacotherapy, but they address the vascular and metabolic conditions closely associated with ED.
The 2026 randomized-trial meta-analysis found a modest improvement of 2.35 points in erectile-function scores from lifestyle intervention, with moderate certainty of evidence. [3]
Consequently, lifestyle therapy should not be dismissed because it is less potent than medication. Its role is different: it may improve erectile function while simultaneously contributing to cardiovascular and metabolic health.
The evidence for supplements requires still greater restraint.
L-arginine produces a small improvement in erectile-function scores, but contemporary guideline interpretation explicitly warns that this change may not be perceptible to patients. [6]
Ginseng provides even weaker evidence of meaningful efficacy.
Commercial supplements present an additional translational problem because the products purchased by consumers often do not reproduce the ingredient doses evaluated in clinical trials. The finding that 80% of evaluated marketed products fell into a “no expected efficacy” category illustrates the difference between evidence for an isolated ingredient and evidence for a commercial formulation. [7]
Therefore, describing all interventions as alternative but roughly equivalent approaches to ED would misrepresent the evidence.
They are not equivalent.
21. Conclusion
Erectile dysfunction should be approached as a multifactorial clinical condition with important sexual, vascular, metabolic, and cardiovascular dimensions.
The current evidence establishes a relatively clear therapeutic hierarchy.
PDE5 inhibitors are the best-supported oral pharmacological treatments for ED and have substantially stronger evidence than nutritional supplements.
Among the four major PDE5 inhibitors, a 2026 network meta-analysis of 83 double-blind randomized trials involving 6,029 participants found sildenafil to have the strongest on-demand efficacy, with sildenafil 100 mg producing the highest efficacy estimate.
Tadalafil remains highly effective and had the lowest treatment-related adverse-event ranking in the same analysis, making it an important option when tolerability, prolonged duration, and flexibility are prioritized.
Vardenafil is highly effective but had the highest treatment-related adverse-event ranking in that analysis, while avanafil was effective but produced lower comparative efficacy estimates than the highest-ranked sildenafil, tadalafil, and vardenafil regimens.
Lifestyle intervention has a legitimate evidence-based role. Randomized-trial meta-analysis demonstrates a modest improvement in erectile function, and dietary patterns associated with cardiovascular health are also associated with better erectile outcomes. These interventions are particularly valuable because ED frequently occurs in the context of cardiometabolic disease.
Among nutritional supplements, L-arginine currently has evidence for a small benefit but is substantially less established than PDE5 inhibitors. Ginseng appears to produce only trivial improvement according to current evidence synthesis. Evidence for folic acid and other antioxidant supplements remains insufficient to justify routine use as established ED treatment.
Commercial multi-ingredient ED supplements deserve particular caution. Evidence supporting an individual ingredient cannot automatically be extrapolated to products containing different combinations or substantially different doses.
The most evidence-based approach is therefore not to choose between “natural” and “medical” treatment. It is to identify the causes and cardiovascular implications of ED, improve modifiable metabolic and lifestyle factors, and select established ED treatment according to efficacy, safety, patient characteristics, and preference.
For patients requiring substantial symptomatic improvement, current evidence clearly favors established PDE5-inhibitor therapy over dietary supplements.
References
1. Köhler TS, Kloner RA, Rosen RC, et al. The Princeton IV Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease. Mayo Clin Proc. 2024;99(9):1500–1517. doi:10.1016/j.mayocp.2024.06.002. PMID: 39115509.
2. Ma J, Wei J, Li J, et al. Current treatment for erectile dysfunction: an umbrella review of systematic reviews and meta-analyses. Aging Male. 2026;29(1):2640765. doi:10.1080/13685538.2026.2640765. PMID: 41792626.
3. Li T, He X, Huang W, Liu G, Feng Q. Efficacy of lifestyle interventions in treating erectile dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Sex Med. 2026;23(6). doi:10.1093/jsxmed/qdag137. PMID: 42143598.
4. Yang B, Wei C, Zhang YC, et al. Association between improved erectile function and dietary patterns: a systematic review and meta-analysis. Asian J Androl. 2025;27(2):239–244. doi:10.4103/aja202485. PMID: 39468798.
5. Salonia A, Bettocchi C, Burnett A, et al. A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials. J Sex Med. 2026;23(7). doi:10.1093/jsxmed/qdag176. PMID: 42296271.
6. European Association of Urology. EAU Guidelines on Sexual and Reproductive Health: Management of Erectile Dysfunction. Current online guideline.
7. Petre GC, Francini-Pesenti F, Vitagliano A, Grande G, Ferlin A, Garolla A. Dietary Supplements for Erectile Dysfunction: Analysis of Marketed Products, Systematic Review, Meta-Analysis and Rational Use. Nutrients. 2023;15(17):3677. doi:10.3390/nu15173677. PMID: 37686709.
Author
Registered Dietitian (Israel)
Founder, Healthy Habits Coaching
Comments